Bayer Targets Lupin Over Generic Natazia

Law360, New York (November 29, 2012, 12:39 PM EST) -- Bayer Pharma AG on Wednesday hit Lupin Ltd. with a patent infringement suit in Delaware federal court, seeking to block the India-based drugmaker's plans to market a generic version of its birth control pill Natazia.

Bayer alleges that Lupin's abbreviated new drug application with the U.S. Food and Drug Administration for oral contraceptive tablets that have the same active ingredients as Natazia pills infringe U.S. Patent Number 8,071,577, which does not expire until May 2026, according to the complaint.

“On information and belief, Lupin included in...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.